Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of gr
Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.
The BioIndustry Association (BIA) has asked new UK Chancellor Rachel Reeves for a nuanced approach to R&D tax credits in the upcoming budget, saying that the life sciences should not be
BioMarin Pharmaceutical has made a couple of appointments aimed at boosting its pipeline, both internally and externally, with C-suite appointments in charge of R&D and business develop
With the implementation of advancing technologies in industry comes the parallel need for suitable upskilling of the workforce – but this doesn’t as yet always pan out, and in today’s pharm
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.